PT2069374E - Solvatos cristalinos de derivados de (1s)-1,5-anidro-1-c-(3- ((fenil)metil)fenil)-d-glucitol com álcoois como inibidores de sglt2 para o tratamento de diabetes - Google Patents
Solvatos cristalinos de derivados de (1s)-1,5-anidro-1-c-(3- ((fenil)metil)fenil)-d-glucitol com álcoois como inibidores de sglt2 para o tratamento de diabetes Download PDFInfo
- Publication number
- PT2069374E PT2069374E PT77844991T PT07784499T PT2069374E PT 2069374 E PT2069374 E PT 2069374E PT 77844991 T PT77844991 T PT 77844991T PT 07784499 T PT07784499 T PT 07784499T PT 2069374 E PT2069374 E PT 2069374E
- Authority
- PT
- Portugal
- Prior art keywords
- phenyl
- anhydro
- diabetes
- alcohols
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81711806P | 2006-06-28 | 2006-06-28 | |
US11/765,481 US7919598B2 (en) | 2006-06-28 | 2007-06-20 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2069374E true PT2069374E (pt) | 2014-10-30 |
Family
ID=38581970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT77844991T PT2069374E (pt) | 2006-06-28 | 2007-06-21 | Solvatos cristalinos de derivados de (1s)-1,5-anidro-1-c-(3- ((fenil)metil)fenil)-d-glucitol com álcoois como inibidores de sglt2 para o tratamento de diabetes |
Country Status (33)
Country | Link |
---|---|
US (3) | US7919598B2 (pt) |
EP (4) | EP2069374B2 (pt) |
JP (6) | JP5313889B2 (pt) |
KR (1) | KR101493102B1 (pt) |
CN (2) | CN103145773B (pt) |
AR (1) | AR061730A1 (pt) |
AU (1) | AU2007265246B2 (pt) |
BR (3) | BR122017021516B8 (pt) |
CA (3) | CA2653344C (pt) |
CL (1) | CL2007001915A1 (pt) |
CO (1) | CO6160299A2 (pt) |
CY (1) | CY1115738T1 (pt) |
DK (1) | DK2069374T4 (pt) |
EA (4) | EA028259B1 (pt) |
ES (3) | ES2769130T3 (pt) |
HK (1) | HK1127359A1 (pt) |
HR (1) | HRP20141007T4 (pt) |
IL (5) | IL195882A (pt) |
MX (3) | MX367155B (pt) |
MY (2) | MY173930A (pt) |
NO (2) | NO346828B1 (pt) |
NZ (4) | NZ589202A (pt) |
PE (2) | PE20120776A1 (pt) |
PH (1) | PH12012500168B1 (pt) |
PL (1) | PL2069374T5 (pt) |
PT (1) | PT2069374E (pt) |
RS (1) | RS53638B2 (pt) |
SG (2) | SG172741A1 (pt) |
SI (1) | SI2069374T2 (pt) |
TW (4) | TWI466876B (pt) |
UA (1) | UA96765C2 (pt) |
WO (1) | WO2008002824A1 (pt) |
ZA (1) | ZA200810475B (pt) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US8198464B2 (en) * | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
US20080287529A1 (en) * | 2007-05-18 | 2008-11-20 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
CN103319445B (zh) * | 2007-12-27 | 2016-01-20 | 阿斯利康公司 | Sglt2抑制剂的晶体结构及其制备方法 |
CN104387354A (zh) * | 2007-12-27 | 2015-03-04 | 阿斯利康公司 | Sglt2 抑制剂的晶体结构及其制备方法 |
KR101516677B1 (ko) * | 2008-01-31 | 2015-05-04 | 고토부키 세이야쿠 가부시키가이샤 | 지방성 간 질환의 치료용 의약 조성물 |
WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
US8518895B2 (en) * | 2008-05-22 | 2013-08-27 | Bristol-Myers Squibb Company | Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same |
JP5820269B2 (ja) * | 2008-05-22 | 2015-11-24 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物 |
US8603989B2 (en) * | 2008-05-22 | 2013-12-10 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
ES2599330T3 (es) * | 2008-08-22 | 2017-02-01 | Theracos Sub, Llc | Proceso para la preparación de inhibidores de SGLT2 |
AU2014201286B2 (en) * | 2008-08-22 | 2015-07-02 | Theracosbio, Llc | Processes for the preparation of SGLT2 inhibitors |
WO2010023594A1 (en) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
PE20120373A1 (es) * | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
US8815894B2 (en) * | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
KR101426180B1 (ko) | 2009-11-02 | 2014-07-31 | 화이자 인코포레이티드 | 디옥사-비시클로[3.2.1]옥탄-2,3,4-트리올 유도체 |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
SI2498758T1 (sl) | 2009-11-13 | 2018-10-30 | Astrazeneca Ab | Formulacije dvoplastnih tablet |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2552442A1 (en) | 2010-03-30 | 2013-02-06 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
SG185525A1 (en) | 2010-05-11 | 2012-12-28 | Janssen Pharmaceutica Nv | Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
JP5837072B2 (ja) | 2010-09-03 | 2015-12-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 水溶性抗酸化剤を使用する製剤 |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2012106303A1 (en) | 2011-02-01 | 2012-08-09 | Bristol-Myers Squibb Company | Pharmaceutical formulations including an amine compound |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AU2012241897C1 (en) | 2011-04-13 | 2017-05-11 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
CA2837627A1 (en) | 2011-06-03 | 2012-12-06 | Boehringer Ingelheim International Gmbh | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2014532639A (ja) * | 2011-10-31 | 2014-12-08 | サイノファーム タイワン,リミティド | Sglt2阻害剤の結晶および非結晶形態 |
EP2597090A1 (en) | 2011-11-28 | 2013-05-29 | Sandoz AG | Crystalline dapagliflozin hydrate |
US8697658B2 (en) | 2011-12-15 | 2014-04-15 | National Health Research Institutes | Glycoside compounds |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
CN103910719B (zh) * | 2012-12-31 | 2018-05-01 | 上海璎黎药业有限公司 | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 |
CN103910769B (zh) * | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
WO2014159151A1 (en) | 2013-03-14 | 2014-10-02 | Msd International Gmbh | Methods for preparing sglt2 inhibitors |
DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
WO2014178040A1 (en) | 2013-04-29 | 2014-11-06 | Mapi Pharma Ltd. | Co-crystals of dapagliflozin |
WO2015040571A1 (en) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Process for the preparation of dapagliflozin |
EP3049397A1 (en) | 2013-09-27 | 2016-08-03 | Sun Pharmaceutical Industries Ltd | Process for the purification of dapagliflozin |
WO2015051484A1 (en) | 2013-10-12 | 2015-04-16 | Theracos, Inc. | Preparation of hydroxy-benzylbenzene derivatives |
EP3063116A1 (en) | 2013-10-31 | 2016-09-07 | Sun Pharmaceutical Industries Ltd | Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene |
EP3862003B1 (en) | 2013-12-17 | 2023-10-25 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
CN105960242A (zh) | 2014-01-23 | 2016-09-21 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
CN104829572B (zh) * | 2014-02-10 | 2019-01-04 | 江苏豪森药业集团有限公司 | 达格列净新晶型及其制备方法 |
WO2015128853A1 (en) | 2014-02-28 | 2015-09-03 | Sun Pharmaceutical Industries Limited | Dapagliflozin compositions |
US20170029398A1 (en) * | 2014-03-06 | 2017-02-02 | Srinivasan Thirumalai Rajan | Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof |
CA2943704C (en) | 2014-04-01 | 2023-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
JP6193513B2 (ja) | 2014-05-19 | 2017-09-06 | ファイザー・インク | Asgpr標的化剤としての置換6,8−ジオキサビシクロ[3.2.1]オクタン−2,3−ジオール化合物 |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
US9676741B1 (en) | 2014-06-23 | 2017-06-13 | Sun Pharmaceutical Industries Limited | Co-crystal of dapagliflozin with citric acid |
KR20160013770A (ko) * | 2014-07-28 | 2016-02-05 | 한미정밀화학주식회사 | 다파글리프로진의 신규 결정질 복합체 및 이의 제조방법 |
AU2015323779B2 (en) | 2014-09-25 | 2018-08-09 | Astrazeneca Ab | Combination of an omega-3 fatty acid and an SGLT-2 inhibitor for treating diseases of the liver |
FI3197429T3 (fi) | 2014-09-25 | 2024-06-12 | Boehringer Ingelheim Vetmedica Gmbh | Yhdistelmähoito sglt2:n estäjillä ja dopamiiniagonisteilla aineenvaihduntahäiriöiden ehkäisemiseksi hevoseläimissä |
CN104496952B (zh) * | 2014-11-28 | 2017-04-19 | 深圳翰宇药业股份有限公司 | 一种达格列净的合成方法 |
EP3226874A1 (en) * | 2014-12-03 | 2017-10-11 | Sun Pharmaceutical Industries Ltd | Processes for the preparation of ertugliflozin |
CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
WO2016147197A1 (en) * | 2015-03-17 | 2016-09-22 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form |
WO2016155578A1 (zh) * | 2015-03-27 | 2016-10-06 | 苏州晶云药物科技有限公司 | 达格列净的新晶型及其制备方法 |
WO2016161995A1 (en) | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
CN106146446B (zh) * | 2015-04-17 | 2019-11-08 | 杭州领业医药科技有限公司 | 达格列净半水合物及其晶型、其制备方法及药物组合物 |
WO2016178148A1 (en) * | 2015-05-05 | 2016-11-10 | Glenmark Pharmaceuticals Limited | Process for preparation of dapagliflozin |
AU2016279075C1 (en) | 2015-06-17 | 2021-04-01 | Otsuka America Pharmaceutical, Inc. | Crystalline compounds |
WO2017042683A1 (en) * | 2015-09-07 | 2017-03-16 | Dr. Reddy's Laboratories Limited | Isolated intermediate of dapagliflozin, process for the preparation of isolated intermediate of dapagliflozin, process for the preparation of dapagliflozin |
US10428053B2 (en) | 2015-09-15 | 2019-10-01 | Laurus Labs Limited | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
WO2017060925A1 (en) * | 2015-10-09 | 2017-04-13 | Harman Finochem Limited | Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof |
US9845303B2 (en) | 2015-10-19 | 2017-12-19 | Cadila Healthcare Limited | Process for the preparation of dapagliflozin |
WO2017088839A1 (en) * | 2015-11-27 | 2017-06-01 | Sunshine Lake Pharma Co., Ltd. | A complex of a glucopyranosyl derivative and preparation method and use thereof |
WO2017099496A1 (ko) * | 2015-12-11 | 2017-06-15 | 동아에스티 주식회사 | 다파글리플로진의 신규 용매화물 및 이의 제조방법 |
WO2017118945A1 (en) | 2016-01-08 | 2017-07-13 | Lupin Limited | Premix of dapagliflozin and process for the preparation thereof |
CN105503802A (zh) * | 2016-01-15 | 2016-04-20 | 中山大学 | 一种达格列净-柠檬酸共晶的制备方法 |
CA3016358A1 (en) | 2016-03-11 | 2017-09-14 | Merck Sharp & Dohme Corp. | Methods of treating or reducing the risk of cardiovascular events and related diseases using sglt-2 inhibitors |
BR112018069782A2 (pt) | 2016-03-31 | 2019-01-29 | Lupin Ltd | composição farmacêutica de dapagliflozina |
US10759772B2 (en) * | 2016-05-02 | 2020-09-01 | Aurobindo Pharma Ltd | Process for the preparation of DL-proline co-crystal of Dapagliflozin |
JP7007300B2 (ja) * | 2016-05-24 | 2022-01-24 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 |
WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
WO2017203229A1 (en) | 2016-05-27 | 2017-11-30 | Cipla Limited | Dapagliflozin premixes |
EP3466940B1 (en) * | 2016-05-28 | 2021-11-17 | Ji Lin Hui Sheng Bio-Pharmaceutical Co., Ltd. | Crystal form of sodium-glucose cotransporter 2 inhibitor |
CN107445932A (zh) * | 2016-05-30 | 2017-12-08 | 上海医药工业研究院 | 达格列净共晶物的制备工艺 |
WO2017221211A1 (en) * | 2016-06-24 | 2017-12-28 | Biocon Limited | Process for the preparation of dapagliflozin and its solvate thereof |
CN107641139A (zh) | 2016-07-22 | 2018-01-30 | 江苏豪森药业集团有限公司 | 达格列净中间体的晶型及其制备方法 |
AU2017344882A1 (en) | 2016-10-19 | 2019-03-28 | Boehringer Ingelheim International Gmbh | Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof |
KR20180058510A (ko) | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
WO2018124497A1 (ko) | 2016-12-30 | 2018-07-05 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 |
KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
US11020412B2 (en) | 2017-03-16 | 2021-06-01 | Inventia Healthcare Limited | Pharmaceutical composition comprising dapagliflozin |
AR112015A1 (es) | 2017-06-09 | 2019-09-11 | Novo Nordisk As | Composiciones sólidas para administración oral |
CN107488156B (zh) * | 2017-09-04 | 2020-05-26 | 上海现代制药股份有限公司 | 一种无定型葡萄糖醇的合成方法 |
MX2020002312A (es) * | 2017-09-29 | 2020-09-17 | Hanmi Pharm Ind Co Ltd | Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina. |
KR102369679B1 (ko) * | 2017-09-29 | 2022-03-04 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
CN108516966A (zh) * | 2017-10-19 | 2018-09-11 | 浙江海正药业股份有限公司 | 达格列净的晶型及其制备方法和用途 |
KR20190115948A (ko) | 2018-04-04 | 2019-10-14 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
JP2021520394A (ja) | 2018-04-17 | 2021-08-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物、処置方法及びその使用 |
KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
MA53175A (fr) | 2018-07-19 | 2021-05-26 | Astrazeneca Ab | Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
SG11202102498UA (en) * | 2018-09-26 | 2021-04-29 | Lexicon Pharmaceuticals Inc | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
CN112789041A (zh) | 2018-10-01 | 2021-05-11 | 阿斯利康(瑞典)有限公司 | 用于降低血清尿酸的组合物 |
CN109705075B (zh) * | 2018-12-13 | 2022-12-23 | 苏中药业集团股份有限公司 | 一种达格列净的纯化方法 |
CN109705076B (zh) * | 2019-01-21 | 2023-03-24 | 苏中药业集团股份有限公司 | 一种达格列净晶型、制备方法及其用途 |
CN111559997A (zh) * | 2019-02-13 | 2020-08-21 | 罗欣药业(上海)有限公司 | 一种达格列净新晶型及其制备方法 |
CN111689936A (zh) * | 2019-03-15 | 2020-09-22 | 罗欣药业(上海)有限公司 | 达格列净新晶型及其制备方法 |
CN114641276A (zh) | 2019-11-07 | 2022-06-17 | 诺和诺德股份有限公司 | 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 |
MX2019014226A (es) * | 2019-11-27 | 2022-09-23 | Alparis Sa De Cv | Nuevas fases sólidas de dapagliflozina. |
CN114727624A (zh) | 2019-11-28 | 2022-07-08 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂在非人哺乳动物的停奶中的用途 |
US20230033410A1 (en) * | 2019-12-24 | 2023-02-02 | Hanmi Pharm. Co.,Ltd. | Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor |
MX2022010090A (es) | 2020-02-17 | 2022-09-02 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos. |
CA3169665A1 (en) | 2020-02-21 | 2021-08-26 | Zaklady Farmaceutyczne Polpharma S.A. | Pharmaceutical composition comprising dapagliflozin |
WO2021176096A1 (en) | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
CA3180674A1 (en) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2021219691A1 (en) | 2020-04-29 | 2021-11-04 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
KR20220007446A (ko) * | 2020-07-10 | 2022-01-18 | 한미약품 주식회사 | 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법 |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2022067724A1 (zh) | 2020-09-30 | 2022-04-07 | 北京睿创康泰医药研究院有限公司 | 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用 |
CN117715640A (zh) | 2021-07-28 | 2024-03-15 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途 |
EP4376830A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
CN114394993B (zh) * | 2021-11-11 | 2023-11-10 | 苏州正济药业有限公司 | 一种达格列净中间体的制备方法 |
CN114213399A (zh) * | 2021-12-20 | 2022-03-22 | 上海启讯医药科技有限公司 | 一种卡格列净丙酮水合物及其制备方法和用途 |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
TW202412756A (zh) | 2022-05-25 | 2024-04-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含sglt-2抑制劑之水性醫藥組合物 |
WO2024033519A1 (en) | 2022-08-12 | 2024-02-15 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
WO2024062310A1 (en) * | 2022-09-22 | 2024-03-28 | Savoi Guilherme | Co-crystals derived from empagliflozin and dapagliflozin with l-proline |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (pt) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
DE3581638D1 (de) | 1984-12-04 | 1991-03-07 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
EP0221025A1 (en) | 1985-10-25 | 1987-05-06 | Sandoz Ag | Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
GR1000959B (el) | 1987-05-22 | 1993-03-16 | Squibb & Sons Inc | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
ES2133158T3 (es) | 1993-01-19 | 1999-09-01 | Warner Lambert Co | Formulacion ci-981 oral, estable y proceso de preparacion del mismo. |
US5340583A (en) | 1993-05-06 | 1994-08-23 | Allergan, Inc. | Antimicrobial lenses and lens care systems |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
AU717743B2 (en) | 1995-12-13 | 2000-03-30 | Regents Of The University Of California, The | Nuclear receptor ligands and ligand binding domains |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
EP2433623A1 (en) | 1998-02-02 | 2012-03-28 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
GEP20033114B (en) | 1998-07-06 | 2003-11-25 | Bristol Myers Squibb Co | Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists, Method for Their Production and Pharmaceutical Compositions Containing the Same |
US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
KR20020014570A (ko) * | 2000-08-18 | 2002-02-25 | 김충섭 | 고체분산화시킨 무정형 이프리플라본의 제조방법 |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
EP1385856B1 (en) | 2001-04-11 | 2006-02-22 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
DK1390377T3 (da) * | 2001-05-22 | 2006-06-19 | Pfizer Prod Inc | Ny krystalform af azithromycin |
PL377687A1 (pl) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą |
WO2003101392A2 (en) * | 2002-05-31 | 2003-12-11 | Transform Pharmaceuticals, Inc. | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
WO2004060347A2 (en) * | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2004061433A1 (en) * | 2002-12-30 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
JP2006516257A (ja) * | 2003-01-03 | 2006-06-29 | ブリストル−マイヤーズ スクイブ カンパニー | C−アリールグルコシドsglt2阻害剤の製造法 |
WO2004076470A2 (en) | 2003-02-27 | 2004-09-10 | Bristol-Myers Squibb Company | A non-cryogenic process for forming glycosides |
NZ542399A (en) * | 2003-03-14 | 2009-01-31 | Astellas Pharma Inc | C-glycoside derivatives and salts thereof |
EP1595880A1 (en) * | 2004-05-13 | 2005-11-16 | Speedel Pharma AG | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists |
SI2298768T1 (en) * | 2004-06-11 | 2013-01-31 | Japan Tobacco Inc | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyridoS2,3-dCpyrimidine derivatives and related compounds for the treatment of cancer |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
CN104829572B (zh) | 2014-02-10 | 2019-01-04 | 江苏豪森药业集团有限公司 | 达格列净新晶型及其制备方法 |
-
2007
- 2007-06-20 US US11/765,481 patent/US7919598B2/en active Active
- 2007-06-21 AU AU2007265246A patent/AU2007265246B2/en active Active
- 2007-06-21 NZ NZ589202A patent/NZ589202A/en unknown
- 2007-06-21 EA EA201490902A patent/EA028259B1/ru not_active IP Right Cessation
- 2007-06-21 SI SI200731535T patent/SI2069374T2/sl unknown
- 2007-06-21 WO PCT/US2007/071749 patent/WO2008002824A1/en active Application Filing
- 2007-06-21 DK DK07784499.1T patent/DK2069374T4/da active
- 2007-06-21 PL PL07784499T patent/PL2069374T5/pl unknown
- 2007-06-21 MX MX2016006205A patent/MX367155B/es unknown
- 2007-06-21 CN CN201310052369.2A patent/CN103145773B/zh active Active
- 2007-06-21 EP EP07784499.1A patent/EP2069374B2/en active Active
- 2007-06-21 NZ NZ589195A patent/NZ589195A/en unknown
- 2007-06-21 MX MX2011009646A patent/MX339143B/es unknown
- 2007-06-21 ES ES17203302T patent/ES2769130T3/es active Active
- 2007-06-21 RS RS20140570A patent/RS53638B2/sr unknown
- 2007-06-21 EA EA201791254A patent/EA035999B1/ru not_active IP Right Cessation
- 2007-06-21 EA EA201171333A patent/EA020428B1/ru not_active IP Right Cessation
- 2007-06-21 CA CA2653344A patent/CA2653344C/en active Active
- 2007-06-21 MY MYPI2014001983A patent/MY173930A/en unknown
- 2007-06-21 CN CN200780024135XA patent/CN101479287B/zh active Active
- 2007-06-21 EP EP15181545.3A patent/EP3045466B1/en active Active
- 2007-06-21 NZ NZ574346A patent/NZ574346A/en unknown
- 2007-06-21 EA EA200900066A patent/EA018229B1/ru not_active IP Right Cessation
- 2007-06-21 UA UAA200900606A patent/UA96765C2/uk unknown
- 2007-06-21 JP JP2009518468A patent/JP5313889B2/ja active Active
- 2007-06-21 NZ NZ589190A patent/NZ589190A/en unknown
- 2007-06-21 CA CA2985797A patent/CA2985797A1/en not_active Abandoned
- 2007-06-21 BR BR122017021516A patent/BR122017021516B8/pt active IP Right Grant
- 2007-06-21 CA CA2924318A patent/CA2924318C/en active Active
- 2007-06-21 SG SG2011047727A patent/SG172741A1/en unknown
- 2007-06-21 MX MX2008015377A patent/MX2008015377A/es active IP Right Grant
- 2007-06-21 BR BRPI0713544A patent/BRPI0713544B8/pt active IP Right Grant
- 2007-06-21 BR BR122017015106A patent/BR122017015106B8/pt active IP Right Grant
- 2007-06-21 ES ES07784499T patent/ES2521665T5/es active Active
- 2007-06-21 MY MYPI20085336A patent/MY148566A/en unknown
- 2007-06-21 SG SG10201402181SA patent/SG10201402181SA/en unknown
- 2007-06-21 EP EP17203302.9A patent/EP3363807B1/en active Active
- 2007-06-21 NO NO20085169A patent/NO346828B1/no unknown
- 2007-06-21 EP EP12152907A patent/EP2457918A3/en not_active Withdrawn
- 2007-06-21 PT PT77844991T patent/PT2069374E/pt unknown
- 2007-06-21 ES ES15181545.3T patent/ES2659862T3/es active Active
- 2007-06-21 KR KR1020087031643A patent/KR101493102B1/ko active IP Right Review Request
- 2007-06-28 TW TW102137967A patent/TWI466876B/zh not_active IP Right Cessation
- 2007-06-28 TW TW096123519A patent/TWI421245B/zh not_active IP Right Cessation
- 2007-06-28 TW TW104129264A patent/TW201546054A/zh unknown
- 2007-06-28 TW TW103140880A patent/TWI519528B/zh not_active IP Right Cessation
- 2007-06-28 AR ARP070102896A patent/AR061730A1/es not_active Application Discontinuation
- 2007-06-28 CL CL2007001915A patent/CL2007001915A1/es unknown
- 2007-07-02 PE PE2011001791A patent/PE20120776A1/es not_active Application Discontinuation
- 2007-07-02 PE PE2007000845A patent/PE20080349A1/es not_active Application Discontinuation
-
2008
- 2008-11-10 ZA ZA2008/10475A patent/ZA200810475B/en unknown
- 2008-12-11 IL IL195882A patent/IL195882A/en active IP Right Grant
- 2008-12-24 CO CO08136743A patent/CO6160299A2/es unknown
-
2009
- 2009-07-16 HK HK09106471.6A patent/HK1127359A1/xx active IP Right Maintenance
-
2011
- 2011-03-16 US US13/049,712 patent/US8501698B2/en active Active
- 2011-07-19 IL IL214181A patent/IL214181A/en active IP Right Grant
- 2011-07-19 IL IL214182A patent/IL214182A/en active IP Right Grant
- 2011-07-19 IL IL214180A patent/IL214180A/en active IP Right Grant
-
2012
- 2012-01-26 PH PH12012500168A patent/PH12012500168B1/en unknown
-
2013
- 2013-05-14 JP JP2013102220A patent/JP5666651B2/ja active Active
- 2013-07-10 US US13/938,763 patent/US9453039B2/en active Active
-
2014
- 2014-10-21 HR HRP20141007TT patent/HRP20141007T4/hr unknown
- 2014-10-29 CY CY20141100887T patent/CY1115738T1/el unknown
- 2014-12-10 JP JP2014250141A patent/JP5937187B2/ja active Active
-
2016
- 2016-05-11 JP JP2016095472A patent/JP2016172758A/ja active Pending
- 2016-05-17 IL IL245688A patent/IL245688A0/en unknown
-
2017
- 2017-07-07 JP JP2017133952A patent/JP2017222681A/ja active Pending
-
2018
- 2018-12-18 JP JP2018236514A patent/JP2019059779A/ja active Pending
-
2022
- 2022-11-17 NO NO20221233A patent/NO347770B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2069374T5 (pl) | Krystaliczne solwaty pochodnych (1s)-1,5-anhydro-1-s-(3-((fenylo)metylo)fenylo)-d-glucytolu z alkoholami jako inhibitory sglt2 do leczenia cukrzycy | |
HK1203959A1 (en) | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2- | |
IL224109A (en) | Isoxazole derivatives for use as fungicides | |
IL199673A0 (en) | 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes | |
ZA201102350B (en) | Pyridin-2-yl-amino-i,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
ZA200806510B (en) | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | |
ZA200904108B (en) | Pyrido-pyrazine derivatives useful as herbicidal compounds | |
ZA200809689B (en) | 1, 3, 4 -Oxadiazole derivatives as DGAT1 inhibitors | |
IL207854A0 (en) | Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol | |
IL178056A0 (en) | Oxadiazolone derivatives as ppar delta agonists | |
IL194575A0 (en) | Thiazolidinedione derivatives as pi3 kinase inhibitors | |
HK1124068A1 (en) | 2-arylindole derivatives as mpges-1 inhibitors | |
IL211267A0 (en) | Oxadiazole derivatives for the treatment of diabetes | |
ZA200809554B (en) | 3-(pyridin-2-yl)-[1,2,4]-triazines for use as fungicides |